Results of a new clinical study establish particular genetic defects in tumors as clinical indicators for successful response to a type of immunotherapy called PD-1 blockade.
Results of a new clinical study establish particular genetic defects in tumors as clinical indicators for successful response to a type of immunotherapy called PD-1 blockade.